NewEdge Advisors’s AYTU BioPharma AYTU Stock Holding History

NewEdge Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$57	Hold	21	–	–	﹤0.01%	4097
2025 Q4	$55	Hold	21	–	–	﹤0.01%	4168
2025 Q3	$39	Hold	21	–	–	﹤0.01%	4057
2025 Q2	$46	Hold	21	–	–	﹤0.01%	3931
2025 Q1	$25	Hold	21	–	–	﹤0.01%	3881
2024 Q4	$36	Hold	21	–	–	﹤0.01%	3828
2024 Q3	$49	Hold	21	–	–	﹤0.01%	3748
2024 Q2	$61	Hold	21	–	–	﹤0.01%	3708
2024 Q1	$64	Hold	21	–	–	﹤0.01%	3717
2023 Q4	$60	Hold	21	–	–	﹤0.01%	3660
2023 Q3	$57	Hold	21	–	–	﹤0.01%	3389
2023 Q2	$34	Hold	21	–	–	﹤0.01%	3446
2023 Q1	$47	Sell	21 -1	-5%	-$3	﹤0.01%	3364
2022 Q4	$0	Buy	+22	New	+$83	﹤0.01%	4088

Other funds holding AYTU

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CAM

Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's AYTU Position: Q1 2026 in Review

NewEdge Advisors held its AYTU BioPharma (AYTU) position steady in Q1 2026 at 21 shares worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #4097.

NewEdge Advisors first reported a position in AYTU in Q4 2022 and has held it in 14 quarters since. The position peaked at $64 in Q1 2024. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

NewEdge Advisors held 21 shares of AYTU BioPharma worth $57 as of Q1 2026.
NewEdge Advisors left its AYTU BioPharma share count unchanged in Q1 2026.
AYTU BioPharma made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #4097 holding.
NewEdge Advisors first reported a position in AYTU BioPharma in Q4 2022 and has held it in 14 quarters since.
NewEdge Advisors's AYTU BioPharma position peaked at $64 in Q1 2024.
37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.